Aspirin study for kidney patients halted early – did the risks outweigh the benefits?

NCT ID NCT03796156

Terminated Disease control Sponsor: University of Southampton Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at whether taking a daily low-dose aspirin could help people with chronic kidney disease avoid their first heart attack or stroke. Over 4,600 participants were randomly assigned to take aspirin or receive usual care. The trial was stopped early, and the final results are not yet clear. Aspirin can reduce blood clots but also raises the chance of dangerous bleeding.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Aspirin (low-dose, 75 mg)
What this could lead to: If it had succeeded, this could have shown that daily low-dose aspirin safely reduces the risk of first heart attack or stroke in people with chronic kidney disease.
What could go wrong: The trial was terminated early, so results are limited. Aspirin also increases bleeding risk, which may outweigh benefits in this population.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLEEDING are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome Hemorrhage hemorrhagic disease cardiovascular disorder prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BLEEDING CARDIOVASCULAR DISEASES CHRONIC KIDNEY DISEASES

Contacts and locations

Locations

Nottingham Clinical Trials Unit

Nottingham, NG7 2RD, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.